Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg (BMY) Stock Price & Analysis

BMY Stock Chart & Stats

23.220.69(3.06%)

At close: Oct 30 4:00 PM EDT

Day’s Range: $23.18 - $23.22
52-Week Range: $22.36 - $23.43
Previous Close: $22.53
Volume: N/A
Average Volume (3M): 996
Market Cap: CAD 178.48B
Enterprise Value: N/A
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: N/A
Next Earnings: Feb 04, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg News

Bristol Myers price target lowered to $40 from $41 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Bristol Myers (BMY) to $40 from $41 and keeps an Underweight rating on the shares. Published first on TheFly – the ultimate

2d agoBMY BRM

Bristol Myers price target lowered to $60 from $65 at Wells Fargo

Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Bristol Myers (BMY) to $60 from $65 and keeps an Equal Weight rating on the shares. The firm sees

2d agoBMY BRM

Bristol-Myers Squibb: Buy Rating Reaffirmed as Strong Q3, Pipeline Catalysts Support Higher $67 Price Target

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on BMY stock, giving a Buy rating yesterday. Jason Gerberry has given his Buy rating due to a

3d agoBMY BRM

Bristol Myers: Solid Q3 Beat but Mixed New Launch Traction and LOE Headwinds Justify Hold Rating

William Blair analyst Matt Phipps has maintained their neutral stance on BMY stock, giving a Hold rating on October 27. Matt Phipps has given his Hold rating due to a

3d agoBMY BRM

Private Markets: Claude developer Anthropic files to go public

Anthropic has publicly filed for a Nasdaq IPO, with the Claude developer widely expected to debut in mid-November at a valuation that could top $2 trillion. Meanwhile, cloud and AI

3d agoAI DE

Midday Fly By: Alphabet plunges, Microsoft dips after earnings

The major averages were broadly lower near noon as investors digest results from Alphabet and Microsoft. Hyperscaler peer Amazon joins the parade with its own earnings report due after the

3d agoON ADT

Psychedelic: Clearmind completes recruitment for AUD cohort of CMND-100 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on recruitment completion, a supply agreement and a subsidiary establishment. CLEARMIND COMPLETES RECRUITMENT

3d agoBMY CMND

Bristol Myers cuts FY26 adjusted EPS view to $6.35-$6.55 from $6.75-$7.00

FY26 consensus $6.54. Raises FY26 revenue view to $49.75B-$50.25B from $49B-$50B, consensus $49.9B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

4d agoBMY BRM

Bristol Myers reports Q3 adjusted EPS $1.35, consensus $1.22

Reports Q3 revenue $13.07B, consensus $12.73B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >>

4d agoBMY BRM

Incyte highlights data across gastrointestinal cancer portfolio at ESMO 2026

Incyte (INCY) announced new results from its advancing oncology portfolio, including updated results for its KRAS G12D inhibitor in pancreatic ductal adenocarcinoma and advanced or metastatic colorectal cancer, and its

6d agoBMY GMAB

Bristol Myers price target lowered to $78 from $82 at Piper Sandler

Piper Sandler lowered the firm’s price target on Bristol Myers (BMY) to $78 from $82 and keeps an Overweight rating on the shares. The firm is reviewing the Q3 cycle

1w agoBMY BRM

Bristol Myers, SystImmune announce results from Phase 3 study of iza-bren

SystImmune and Bristol Myers (BMY) Squibb announced that SystImmune’s parent company Sichuan Biokin reported positive results from a prespecified interim analysis in the randomized, multicenter Phase 3 PANKU-Lung01 study evaluating

1w agoBMY BRM

BMY FAQ

What was Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg’s price range in the past 12 months?

Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg lowest stock price was C$22.36 and its highest was C$23.43 in the past 12 months.

What is Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg’s market cap?

Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg’s market cap is C$178.48B.

When is Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg pay dividends?

Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg does not currently pay dividends.

What is Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg’s EPS estimate?

Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg have?

Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg has 2,044,086,000 shares outstanding.

Which hedge fund is a major shareholder of Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg?

Currently, no hedge funds are holding shares in TSE:BMY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg (BMY) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	2	0	0
Technical Analysis	0	0	0
Moving Averages	2	0	0

Technical Analysis >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft